Nasdaq:US$15.16 (+0.08) | HKEX:HK$23.10 (-0.40) | AIM:£2.25 (+0)
Search
Commercialization in China
Over the past two decades, we have operated in China’s complex and evolving medical system.

We built a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as third-party prescription drugs in China.

For investors, more information can be found under the Shareholder Information section of this website.

Commercializing Oncology Innovations
Leveraging Established China Prescription Drug Commercial Infrastructure

Our more than 20 years of track record and deep institutional knowledge of prescription drug marketing and distribution process are being leveraged to bring our in-house innovations to patients.

We have established a dedicated oncology-focused commercial team in China to support the launch of products emerging from our innovative pipeline. An approximately 770-person oncology commercial organization is in place, covering over 3,000 oncology hospitals and over 33,000 oncology physicians in 30 provinces and municipalities in China. The team is now responsible for the commercialization of ELUNATE® (fruquintinib), SULANDA® (surufatinib) and TAZVERIK® (tazemetostat) in China.

Outside of China, we intend to commercialize our products, if approved, in the United States, Europe and other major markets through partnerships with leading biopharmaceutical companies.

Our commercial operations adhere to multi-national compliance standards and are adaptable to multiple therapeutic areas. It had successfully marketed many third-party products for multi-national corporations in China.

Dedicated oncology commercial team in China

  • ~770 oncology-specialized salespeople
  • Covering 30 provinces and municipalities
  • Over 3,000 key hospitals and cancer centers and 30,000+ oncology physicians
  • Currently responsible for the commercialization of two of our approved and launched oncology drugs in China.

Fruquintinib
(ELUNATE® in China)

Surufatinib
(SULANDA® in China)